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Abstract 
	Angiogenesis is the process by which new blood vessels form, as 
cells undergoing hypoxia secrete Vascular Endothelial Growth Factor 
(VEGF), which prompts a tip cell phenotype in adjacent endothelial 
cells. The new tip cell expresses DLL4 and presents it on its surface, 
which binds to Notch receptors on neighboring cells and inhibits them 
from also becoming tip cells, forcing them to adopt the stalk cell 
phenotype. Notch signaling is critical to the tip/stalk cell fate decision, 
and both Notch1 and Notch4 are expressed in the vasculature, but not 
much is known about the different roles and parallel functions of 
Notch4 in contrast to the well-studied Notch1. In order to quantify the 
effects of removing Notch4, Notch4 mutants were generated via 
genetic mutations, or Notch4 function was inhibited by an anti-Notch4 
neutralizing antibody. The vasculature of postnatal retina from control 
animals was compared to either knockout or anti-Notch4 treated mice 
on measures of radial outgrowth, tip cell count, vascular density, large 
vessels count, and branching. The experimental groups were then 
compared to each other to understand the degree to which 
pharmacologic inhibition recapitulates the genetic knockout 
phenotype.  
 Our data shows that the Notch4 genetic knockout mice tend to 
exhibit decreased radial outgrowth and reduced branching. This 
supports the hypothesis that Notch1 and Notch4 have unique targets, 
as Notch1 knockouts show a stark increase in tip cell density, which is 
not seen in Notch4 genetic knockouts. In contrast, the pharmacologic 
Notch4 knockouts resembled the Notch4 genetic knockouts in radial 
outgrowth, but Notch1 mutants in tip cell density, though the reason 
why is not yet known. 
 The mapping of angiogenic pathways is of consequence because it 
offers many avenues for studying human health. For example, new 
cancer research aims to reduce blood flow to tumors by decreasing 
angiogenesis, and published data suggests that knocking out Notch4 
reduces tumor perfusion and growth. Therefore, a deeper 
understanding of the role of Notch4, and in turn, angiogenesis, could 
aid the development of new medicinal therapies for some of our most 
deadly diseases.  
	
 The Canonical Notch Pathway 
The Notch family of proteins are membrane-
bound receptors that use canonical signaling to 
affect expression of downstream genes. In short, 
once bound by one of its ligands, the 
intracellular domain is cleaved and forms a 
transcriptional complex with other proteins 
which translocates to the nucleus to regulate 




The Retinal Model of Angiogenesis 
James et al., 2014 
Biochim Biophys Acta. 
Validation of Notch4 Genetic Null 
Hoffman and Iruela-Arispe 
Gene Exp. Patterns, 2007 
These are retina that have been stained 
for Notch4 in red and vasculature in 
green. The overlap between the red and 
the green in different parts of the retina 
shows that Notch4 is expressed in 
retinal vasculature, making retina a 
valid model for studying Notch4 and 
its relation to angiogenesis. 
Because mice are born 
without developed 
vasculature in their eyes, 
the retinal model is perfect 
for studying angiogenesis, 
or the development of 
vasculature. At P5, or post-
natal day 5, immature, 
remodeling, and mature 
vasculature are all present, 
which is why all results 
shown are from mice 
harvested at P5.  
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Protocol Overview 
1.  Inject P1 pups with either tamoxifen to induce gene 
excision from genetic nulls or anti-Notch4 antibody 
to inhibit Notch4 in pharmacologic nulls 
2.  Harvest eyes from P5 pups 
3.  Dissect out retina from eyes 
4.  Stain retina with biotinylated isolectin b4 primary 
antibody (which stains vasculature) and 
streptavidin-conjugated Alexaflor 647 (which will 
attach to the primary antibody and fluoresce) 
5.  Cut slits in spherical retina and mount on 
microscope slides 
6.  Image retina using florescence microscopy 
7.  Quantify data via image analysis using Fiji 
Quantification Overview 
Radial outgrowth: 
Distance from the center 
of the retina (optic nerve) 
to the edge of the 
vasculature. 
Measurements taken 
from each lobe and 
averaged.  
Tip cell count: Tip cells 
were identified by 
presence of filopodia, 
counted, and divided by 
the length of the vascular 
front to correct for retina 
with greater 
circumference.  
Branch point density: 
Each branch point was 
counted within a vascular 
front with constant depth 
between samples.  
Front density: The 
percentage of the front 
covered by vasculature 
was quantified.  
Capillary density: The 
percentage of the 
capillary front, defined 
as the space between 
major veins and arteries, 
covered by vasculature 
was quantified 
 
Central Vessel Count: 
Vessels protruding from 
the center of the retina 
were counted.  
Vessel Diameter:  The 
diameter across vessels 
included in the central 





























































































































•  Increase sample size for genetic loss experiment to see 
if trends become statistically significant 
•  Repeat pharmacologic loss experiment to see if 
statistically significant results are reproducible 
•  Repeat genetic loss experiment while keeping 
heterozygotes separate from wildtype homozygotes to 
test for possible haploinsufficiency 


























































Mice that were both homozygous for the N4 mutant 
allele (labeled as N4hom) and who were Cre+ (as it is 
Cre recombinase that actually makes excision possible) 
were considered Notch 4 nulls as they would have no 
functioning copy of the Notch gene. All other mice 
were considered controls as they would have at least 
one functioning copy of the gene. This gel 
electrophoresis of products from polymerase chain 
reaction demonstrates that the excision of the Notch 4 
gene worked as expected as the nulls express the mutant 
band as expected.  
 
Control Retina Notch 4 Null Retina 
Mutant vasculature trends towards being smaller and less dense.  
The genetic null shows a trend towards decreased radial 
outgrowth, which is consistent with the pharmacologic 
null. One hypothesis for this in the literature is that a loss 
of Notch4 upregulates adhesion factors that cement the 
endothelial cells in place and make it hard for the cells to 
migrate forwards. In addition, the outlier data point in each 
of these measurements is from the same sample, which 
leads us to believe that an increased sample size may very 
well convert trends into statistical significance.  
*All error bars are standard error of the mean, all reported P values are from two-tailed T-
test for equal variances.   
 Pharmacologic Loss of Notch4 
The pharmacologic null uses an antibody that inhibits 
Notch4 function. The control group received 1 dose of 
nonspecific immunoglobulin G. The data shows a 
statistically significant reduction in radial outgrowth and 
vein diameter and  and a trend towards increased tip cells 
per mm in the experimental group. The reduced radial 
outgrowth is consistent with the genetic Notch4 null, 
however the increased tip cell density is not seen in the 
Notch4 genetic null and is consistent with a genetic loss of 
Notch1 function.   
Conclusions 
•  Pharmacologic loss of Notch4 correlates with reduced radial 
outgrowth, which seems to be consistent with genetic loss.  
•  Pharmacologic loss of Notch4 correlates with reduced vein 
diameter, which is also a phenotype of Notch4 gain-of-
function, suggesting a bell-curve response.  
•  Pharmacologic loss of Notch4 is trending towards increased 
tip cell density, which is not seen in the Notch4 genetic null 
but is seen in the Notch1 null.  
•  The pharmacologic null does recapitulate the genetic null in 
some aspects, but not in others.  
James et al., 2014, Biochim Biophys Acta. 
Wildtype  Heterozygote  Null 
In this model of Notch4 null, 
the heterozygote has a 
stronger phenotype than the 
true null, indicating there is a 
possibility that Notch4 is 
haploinsufficient. However, 
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